These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 10187802

  • 1. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate.
    Meng Q, Malinovskii V, Huang W, Hu Y, Chung L, Nagase H, Bode W, Maskos K, Brew K.
    J Biol Chem; 1999 Apr 09; 274(15):10184-9. PubMed ID: 10187802
    [Abstract] [Full Text] [Related]

  • 2. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases.
    Huang W, Meng Q, Suzuki K, Nagase H, Brew K.
    J Biol Chem; 1997 Aug 29; 272(35):22086-91. PubMed ID: 9268350
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition.
    Lee MH, Rapti M, Knaüper V, Murphy G.
    J Biol Chem; 2004 Apr 23; 279(17):17562-9. PubMed ID: 14734567
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
    Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG.
    Circulation; 1998 May 05; 97(17):1708-15. PubMed ID: 9591765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.
    Iyer S, Wei S, Brew K, Acharya KR.
    J Biol Chem; 2007 Jan 05; 282(1):364-71. PubMed ID: 17050530
    [Abstract] [Full Text] [Related]

  • 9. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2.
    Olson MW, Gervasi DC, Mobashery S, Fridman R.
    J Biol Chem; 1997 Nov 21; 272(47):29975-83. PubMed ID: 9368077
    [Abstract] [Full Text] [Related]

  • 10. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study].
    Matsumoto F, Uzuki M, Kaneko C, Rikimaru A, Kokubun S, Sawai T.
    Ryumachi; 1997 Oct 21; 37(5):688-95. PubMed ID: 9396371
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors.
    Wei S, Chen Y, Chung L, Nagase H, Brew K.
    J Biol Chem; 2003 Mar 14; 278(11):9831-4. PubMed ID: 12515831
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
    Vaillant C, Didier-Bazès M, Hutter A, Belin MF, Thomasset N.
    J Neurosci; 1999 Jun 15; 19(12):4994-5004. PubMed ID: 10366632
    [Abstract] [Full Text] [Related]

  • 15. Matrix metalloproteinases and their inhibitors.
    Kugler A.
    Anticancer Res; 1999 Jun 15; 19(2C):1589-92. PubMed ID: 10365151
    [Abstract] [Full Text] [Related]

  • 16. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
    Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K.
    EMBO J; 1998 Sep 01; 17(17):5238-48. PubMed ID: 9724659
    [Abstract] [Full Text] [Related]

  • 17. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy.
    Webster L, Chignell AH, Limb GA.
    Exp Eye Res; 1999 Jan 01; 68(1):91-8. PubMed ID: 9986746
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.
    Raeeszadeh-Sarmazdeh M, Greene KA, Sankaran B, Downey GP, Radisky DC, Radisky ES.
    J Biol Chem; 2019 Jun 14; 294(24):9476-9488. PubMed ID: 31040180
    [Abstract] [Full Text] [Related]

  • 20. Collagenase-1, stromelysin-1 and 92 kDa gelatinase are associated with tumor necrosis factor-alpha induced morphological change of human endothelial cells in vitro.
    Nelimarkka LO, Nikkari ST, Ravanti LS, Kähäri VM, Järveläinen HT.
    Matrix Biol; 1998 Aug 14; 17(4):293-304. PubMed ID: 9749945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.